Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 18/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13114842 | 0.90 | AR (0.55) | ARCYP2C19 | |
| SCHEMBL13114852 | 0.88 | AR (0.53) | ARROCK2ROCK1CDC42BPBCYP2C19 | |
| SCHEMBL13114843 | 0.88 | AR (0.53) | ARCYP2C19 | |
| SCHEMBL13114859 | 0.87 | AR (0.49) | ARROCK2ROCK1CDC42BPB | |
| SCHEMBL13114854 | 0.86 | AR (0.51) | ARCYP2C19 | |
| SCHEMBL3579221 | 0.86 | AR (0.51) | ARCYP2C19 | |
| SCHEMBL13114872 | 0.85 | AR (0.47) | ARROCK2ROCK1CDC42BPB | |
| SCHEMBL13114851 | 0.85 | AR (0.47) | ARROCK2ROCK1CDC42BPB | |
| SCHEMBL13114868 | 0.85 | AR (0.52) | ARCYP2C19 | |
| SCHEMBL3576091 | 0.83 | AR (0.46) | ARROCK2ROCK1CDC42BPBCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807691-B2 | Substituted N-arylpyrrolidines as selective androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807691-B2 | Substituted N-arylpyrrolidines as selective androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807691-B2 | Substituted N-arylpyrrolidines as selective androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1891038-B1 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1891038-B1 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | ELI LILLY AND COMPANY | 2008-07-24 | — | — | US | disclosed |
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | ELI LILLY AND COMPANY | 2008-07-24 | — | — | US | disclosed |
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | ELI LILLY AND COMPANY | 2008-07-24 | — | — | US | disclosed |
| EP-1891038-A2 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006124447-A2 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | AR, FSHR, SHBG | AR 1/4885ROCK2 2694/4885ROCK1 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.